Drug Recall

 

HPS Pharmacies wish to advise that Pfizer Australia Pty Ltd, in consultation with the Therapeutic Goods Administration (TGA) have given notice of a drug recall of:

Product

Generic

Description

Aust R

Group 1

Halcion® triazolam 0.125mg tablets x 50 12304
Pontsan® mefenamic acid 250mg capsules x 50 <p”>14387
Xanax® alprazolam 2mg tablets x 50 53931

Group 2

Dostinex® cabergoline 0.5mg tablets x 2 and 8 52158
Cabaser® cabergoline 1mg tablets x 30

2mg tablets x 30

57360

57367

Methoblastin® methotrexate 2.5mg tablets x 30

10mg tablets x 30

15418

15417

 

This recall has been issued due to these products being supplied in containers without child-resistant closures, which presents a risk to children of accidental ingestion of these poisons. There is no concern with the quality or safety of the tablets or capsules themselves.

The products described in Group 1 above are subject to a full recall. In order to maintain continuity of therapy for patients, the recall of the products in Group 2 is to enable correction, by fitting child-resistant closures.

This recall includes all batches and all expiry dates of the above named products, however it does not include the Schedule 2 Pharmacy Medicine Ponstan® 250mg capsules in blister packs of 20, AUST R 14388.

As a result of this recall, Halcion® 200mg tablets x 50 and Ponstan® 250mg capsules x 50 will be unavailable until further notice. Xanax® was discontinued from the Australian market in December 2013. Alternative brands are available of alprazolam 2mg and methotrexate 2.5mg tablets.

Please inspect your stocks and quarantine all products listed above. Those items from Group 1 should be returned to your supplier for a refund. Those items from Group 2 should have the closure replaced with one that is child-resistant, obtained by submitting an Acknowledgement Form to Pfizer before 20th March, 2015. Any items supplied by HPS Pharmacies may be returned to the pharmacy for processing.

Retain this notice in a prominent position, including in other related business units for one month, or until normal supply resumes. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies, or Pfizer Medical Information on 1800 675 229.

Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates